IL229583B - A preparation obtained by a process for the purification of coagulation factor viii - Google Patents

A preparation obtained by a process for the purification of coagulation factor viii

Info

Publication number
IL229583B
IL229583B IL229583A IL22958310A IL229583B IL 229583 B IL229583 B IL 229583B IL 229583 A IL229583 A IL 229583A IL 22958310 A IL22958310 A IL 22958310A IL 229583 B IL229583 B IL 229583B
Authority
IL
Israel
Prior art keywords
factor viii
composition obtained
coagulation factor
purifying coagulation
purifying
Prior art date
Application number
IL229583A
Other languages
English (en)
Hebrew (he)
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40076764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL229583(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Octapharma Ag filed Critical Octapharma Ag
Publication of IL229583B publication Critical patent/IL229583B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3847—Multimodal interactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
IL229583A 2008-06-24 2010-12-05 A preparation obtained by a process for the purification of coagulation factor viii IL229583B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12940208P 2008-06-24 2008-06-24
EP08158893 2008-06-24
PCT/EP2009/057883 WO2009156430A1 (en) 2008-06-24 2009-06-24 A process of purifying coagulation factor viii

Publications (1)

Publication Number Publication Date
IL229583B true IL229583B (en) 2018-03-29

Family

ID=40076764

Family Applications (3)

Application Number Title Priority Date Filing Date
IL229583A IL229583B (en) 2008-06-24 2010-12-05 A preparation obtained by a process for the purification of coagulation factor viii
IL209758A IL209758A (en) 2008-06-24 2010-12-05 Process for purifying or enriching coagulation factor viii
IL229583A IL229583A0 (en) 2008-06-24 2013-11-24 A process for the purification of coagulation factor viii

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL209758A IL209758A (en) 2008-06-24 2010-12-05 Process for purifying or enriching coagulation factor viii
IL229583A IL229583A0 (en) 2008-06-24 2013-11-24 A process for the purification of coagulation factor viii

Country Status (19)

Country Link
US (1) US8329871B2 (enExample)
EP (2) EP2300497B1 (enExample)
JP (1) JP5619738B2 (enExample)
KR (3) KR101700722B1 (enExample)
CN (1) CN102066417B (enExample)
AU (1) AU2009264282B2 (enExample)
BR (1) BRPI0914695B1 (enExample)
CA (1) CA2728047C (enExample)
DK (2) DK2537862T3 (enExample)
ES (2) ES2538706T3 (enExample)
IL (3) IL229583B (enExample)
MX (1) MX2010013908A (enExample)
PL (1) PL2300497T3 (enExample)
PT (1) PT2300497E (enExample)
RU (2) RU2698392C2 (enExample)
SI (1) SI2300497T1 (enExample)
UA (1) UA100901C2 (enExample)
WO (1) WO2009156430A1 (enExample)
ZA (1) ZA201009162B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5323072B2 (ja) 2007-07-11 2013-10-23 ノボ・ノルデイスク・エー／エス 混合方式又は多様式樹脂を使用する第ｖｉｉｉ因子の精製
EP2027875A1 (en) * 2007-08-23 2009-02-25 Octapharma AG A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC)
BRPI0917656A2 (pt) 2008-08-21 2017-07-11 Octapharma Ag Fatores viii e ix humanos produzidos de forma recombinante
SI2337580T1 (sl) * 2008-09-03 2012-06-29 Octapharma Ag Stabilizirani sestavki za rekombinanto proizveden faktor VIII
WO2010030222A1 (en) * 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal with multimodal anion exchangers in the presence of protein-excluded zwitterions
TR201911082T4 (tr) * 2010-03-30 2019-08-21 Octapharma Ag K vitaminine bağımlı proteinlerin saflaştırılması için bir işlem.
KR101951446B1 (ko) 2010-03-30 2019-02-22 옥타파마 아게 성장 인자 단백질을 정제하는 방법
AU2011244348B2 (en) 2010-04-20 2015-02-12 Octapharma Ag New stabilizing agent for pharmaceutical proteins
WO2012049285A1 (en) 2010-10-14 2012-04-19 Octapharma Ag A method for the quantitative glycosylation analysis of proteins
MX342235B (es) 2010-11-05 2016-09-21 Hoffmann La Roche Metodo optimizado para captura de anticuerpo por cromatografia de modo mixto.
EP3626737B1 (en) * 2011-05-13 2023-11-29 Octapharma AG A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii
CN103688177B (zh) 2011-06-17 2017-07-04 学校法人东日本学园 狼疮抗凝物检测用血液凝固时间的测定方法
US20130109807A1 (en) * 2011-10-26 2013-05-02 Bio-Rad Laboratories, Inc. Removal of virucidal agents in mixed mode chromatography
WO2014066471A1 (en) * 2012-10-24 2014-05-01 Genzyme Corporation Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins
CN103880947B (zh) * 2012-12-21 2016-01-13 武汉禾元生物科技股份有限公司 一种分离纯化高纯度重组人血清白蛋白的层析方法
IL274646B (en) * 2013-03-08 2022-09-01 Genzyme Corp Integrated continuous production of medicinal substances from medical protein
US20160130361A1 (en) * 2013-06-13 2016-05-12 Biogen Ma Inc. Anti-factor viii antibodies or uses thereof
EP3019262A1 (en) 2013-07-12 2016-05-18 Merck Patent GmbH Removal of fragments from a sample containing a target protein using activated carbon
US10947269B2 (en) 2013-08-08 2021-03-16 Bioverativ Therapeutics Inc. Purification of chimeric FVIII molecules
CN105579468A (zh) 2013-09-24 2016-05-11 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
TWI709570B (zh) * 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
EP3097118B1 (en) 2014-01-20 2018-07-18 Octapharma AG A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag
HUE051470T2 (hu) * 2014-01-24 2021-03-01 Am Pharma Bv Egy alkalikus foszfatáz feldolgozási folyamata
EP3102589A1 (en) * 2014-02-04 2016-12-14 Biogen MA Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
CN104861060A (zh) * 2014-02-21 2015-08-26 神州细胞工程有限公司 一种纯化凝血因子viii的方法
WO2015183183A1 (en) 2014-05-29 2015-12-03 Agency For Science, Technology And Research Protein Extraction Methods
US10626164B2 (en) * 2014-07-25 2020-04-21 Csl Limited Purification of VWF
GB201506117D0 (en) * 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
GB201506113D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
WO2016207328A1 (en) * 2015-06-24 2016-12-29 Glycotope Gmbh PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES
EP3205665A1 (en) 2016-02-11 2017-08-16 Octapharma AG Method of separating factor viii from blood products
GB201617240D0 (en) * 2016-10-11 2016-11-23 Profactor Pharma Ltd Purification process
JP7253505B2 (ja) * 2017-06-23 2023-04-06 武田薬品工業株式会社 第ｖｉｉｉ因子亜種の精製
CN107226859B (zh) * 2017-08-10 2020-11-24 博雅生物制药集团股份有限公司 一种人凝血因子ⅷ的制备方法
WO2019045149A1 (en) * 2017-08-31 2019-03-07 Green Cross Corporation PROCESS FOR PURIFYING SULFATASE PROTEIN
CN111511800B (zh) 2017-10-30 2023-11-28 武田药品工业株式会社 灭活脂包膜病毒的环境相容性去污剂
BR112021003420A2 (pt) 2018-08-31 2021-05-18 Genzyme Corporation resina cromatográfica estéril e uso da mesma em processos de manufatura
KR20220130692A (ko) * 2020-01-20 2022-09-27 우시 바이올로직스 아일랜드 리미티드 친화성 크로마토그래피를 위한 신규한 세척 완충제 용액
CN118217951B (zh) * 2024-04-01 2025-05-23 山东建筑大学 一种水中的高纯度磷回收装置和方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US5316680A (en) 1992-10-21 1994-05-31 Cornell Research Foundation, Inc. Multimodal chromatographic separation media and process for using same
EP0711485B1 (en) 1993-06-11 1997-04-16 Nortel Networks Corporation Method for providing user controlled call management services
DE4337573C1 (de) * 1993-11-04 1995-05-18 Octapharma Ag Verfahren zur Herstellung einer virusinaktivierten Faktor VIII enthaltenden Fraktion mittels chromatographischer Methoden
SE9403915D0 (sv) 1994-11-14 1994-11-14 Annelie Almstedt Process A
AUPR638801A0 (en) * 2001-07-13 2001-08-09 Life Therapeutics Limited Factor viii separation
EP1718386A1 (en) * 2004-02-27 2006-11-08 GE Healthcare Bio-Sciences AB A process for the purification of antibodies
EP2277912B1 (en) * 2004-06-07 2016-09-28 Therapure Biopharma Inc. Isolation of plasma proteins
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
FR2887883B1 (fr) * 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
NZ573639A (en) 2006-07-14 2012-03-30 Genentech Inc Refolding of recombinant proteins
RU2324495C1 (ru) * 2006-08-31 2008-05-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Способ получения препарата фактора свертывания viii крови человека
US8022187B2 (en) * 2007-02-01 2011-09-20 Baxter International Inc. FVIII-independent FIX-mutant proteins for hemophilia A treatment
US9107902B2 (en) * 2007-06-13 2015-08-18 Csl Behring Gmbh Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
JP5323072B2 (ja) 2007-07-11 2013-10-23 ノボ・ノルデイスク・エー／エス 混合方式又は多様式樹脂を使用する第ｖｉｉｉ因子の精製
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie

Also Published As

Publication number Publication date
CN102066417A (zh) 2011-05-18
MX2010013908A (es) 2011-01-21
DK2537862T3 (en) 2015-06-15
WO2009156430A1 (en) 2009-12-30
EP2537862B1 (en) 2015-03-18
KR20160104740A (ko) 2016-09-05
EP2537862A1 (en) 2012-12-26
RU2015141849A (ru) 2018-12-28
DK2300497T3 (da) 2012-10-29
IL229583A0 (en) 2014-01-30
JP2011525523A (ja) 2011-09-22
IL209758A0 (en) 2011-02-28
JP5619738B2 (ja) 2014-11-05
CN102066417B (zh) 2015-11-25
KR20170102065A (ko) 2017-09-06
BRPI0914695A2 (pt) 2015-10-20
CA2728047A1 (en) 2009-12-30
AU2009264282B2 (en) 2013-04-18
UA100901C2 (ru) 2013-02-11
RU2011102437A (ru) 2012-07-27
US20110160435A1 (en) 2011-06-30
AU2009264282A1 (en) 2009-12-30
IL209758A (en) 2014-02-27
PT2300497E (pt) 2012-10-30
BRPI0914695B1 (pt) 2022-04-19
US8329871B2 (en) 2012-12-11
KR101700722B1 (ko) 2017-01-31
RU2567811C2 (ru) 2015-11-10
EP2300497A1 (en) 2011-03-30
EP2300497B1 (en) 2012-08-08
ES2391613T3 (es) 2012-11-28
KR101804136B1 (ko) 2017-12-04
RU2698392C2 (ru) 2019-08-26
KR20110038634A (ko) 2011-04-14
PL2300497T3 (pl) 2013-02-28
RU2015141849A3 (enExample) 2018-12-28
CA2728047C (en) 2019-07-30
ES2538706T3 (es) 2015-06-23
ZA201009162B (en) 2011-10-26
SI2300497T1 (sl) 2013-02-28

Similar Documents

Publication Publication Date Title
IL229583B (en) A preparation obtained by a process for the purification of coagulation factor viii
EP2271615A4 (en) NEW PROCESS FOR THE PREPARATION OF THE IOPROMIDE
EP2334328A4 (en) METHOD FOR CLEANING VIRUSES
EP2345688A4 (en) METHOD FOR PRODUCING A RESIN COMPOSITION
IL211556A0 (en) Process for the preparation of pramlintide
ZA201106577B (en) Compounds and compositions for cognition-enhancement,methods of making,and methods of treating
PL2151428T3 (pl) Nowy sposób syntezy agomelatyny
SG10201408508YA (en) Combination composition useful for treating cardiovascular diseases
GB0808908D0 (en) Purification process
PL2480523T3 (pl) Sposób wytwarzania N-acylobifenyloalaniny
EP2283146A4 (en) PROCESSES FOR PRODUCING BACTERIAL ALGINATES
GB0914995D0 (en) Micotome for producing sections of specimens
EP2344468A4 (en) PROCESS FOR PREPARING RAMELTÉON
EG26332A (en) Process for the preparation of benzonoprons
IL207911A0 (en) Method for the purification of biological macromolecules
SI2151429T1 (sl) Postopek za pripravo agomelatina
IL207190A (en) A process for ultra-purification of alginates
ZA201009149B (en) Process of making alkylaromatics using emm-12
ZA201100752B (en) Process for the purification of methanol by distillation
ZA201006135B (en) Process for the manufacture of [phenylsufanylphenyl]piperidines
GB2459738B (en) Method of purification
IL211266A (en) Process for adding thiols to alpha, beta-unsaturated beta compounds of sulfonyl or sulfonyl
ZA201008092B (en) Composition and process for the purification of contamanited water
GB0811505D0 (en) Purification process
IL211382A0 (en) Process for the preparation of ethanedinitrile

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed